99
Alphamab Oncology
9966.HK · HKSE
$8.41 +0.06% (+$0.01)
1M -2.44%
Market Cap ¥6.94B
P/E Ratio -
Div. Yield -
ROE 6.28%
Bulios Fair Price
$5.46
35.0% downside
Current Price
$8.41
Undervalued Fair Value Overvalued
According to Bulios Fair Price, 9966.HK is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
6/9Valuation
25 /100
Expensive P/S 12.57x
P/B 4.05x
P/E N/A
Growth
87 /100
Growing Rev. growth 48.97%
Book val. growth 3.19%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 77.35%
Net margin 20.12%
Op. margin 27.07%
Quality
3 /100
Poor ROIC 8.06%
ROE 6.28%
ROA 5.29%
Debt
69 /100
Low Debt/Equity 0.07x
Current ratio 5.67x
Int. coverage -20.58x
Stability
24 /100
Unstable Beta 0.57x
Rev. volatility 108.54%
EPS volatility 175.02%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about 9966.HK
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Ting Xu
Employees
515
Headquarters
Suzhou
Upcoming events
30 MAR
Earnings
Upcoming earnings report